Schwabe’s clinical research on phytomedicines derived from Ginkgo biloba, Saw Palmetto, Hawthorn and St. John’s Wort, to name but a few, has significantly contributed to the acceptance of science-based phytotherapy in the medical community.
The efficacy and safety of our products are investigated in clinical trials prior to their introduction into the markets. Such trials are performed and monitored by our own clinical research unit in accordance with the ICH -GCP guidelines.

The research process for an innovative phytomedicine starts with the screening of new plants.

Schwabe's natural compound research specialists and chemists then produce extracts of the plant using different solvents and extraction methods.

They seek to characterise pharmacologically active ingredients in order to increase their content in the finished product by modifying the extraction procedures. Both the extracts as well as isolated active substances are subsequently tested with regard to their therapeutic action by means of a high performance screening system. For this purpose Schwabe takes advantage of modern drug discovery tools such as microarrays.